Dr. Bennett will give an online talk for the Psychiatry Residents at Essex University. Other licensed medical and mental health professionals who are based in Europe are also welcome to attend at no charge. Advance registration is required.
Title: Paradigms for Ketamine Treatment
Date: Tuesday, October 18, 2002
Time: 11:00 AM (San Francisco) / 7:00 PM (London)
Duration: 90 minutes
Eligibility: European clinicians only
Link: Click here to register
Description: Ketamine is a unique and powerful tool with many clinical applications. In this talk, Dr. Bennett will focus on the use of racemic (generic) ketamine for mental health indications. She will provide a conceptual overview of three different paradigms for ketamine treatment: biochemical/medical, psychotherapeutic/relational, and psychedelic/shamanic. Then Dr. Bennett will talk about the clinical indications for ketamine treatment, including the established and investigational uses, according to the most current research literature. If there is time, Dr. Bennett will talk about some of the current controversies in this burgeoning field. This talk will be followed by live Q&A with Dr. Bennett (with moderation by Dr. Nicolas Blondel).
Speaker: Raquel Bennett, Psy.D. is a psychologist and ketamine specialist from Berkeley, California, USA. She has been studying the use of racemic ketamine for refractory depressive disorders (and other mental health indications) since 2002. She also has a long-standing interest in the psychedelic and mystical properties of ketamine, and the potential for this medicine to be used for spiritual exploration. Dr. Bennett is the founder of KRIYA Institute and KRIYA Conference, which are both devoted to the use of ketamine in psychiatry and psychotherapy. She has given hundreds of lectures and trained thousands of clinicians worldwide on the safe and legal use of ketamine in clinical practice. You can learn more about her work at: www.kriyainstitute.com
1. Bahji, A., Zarate, C., & Vasquez, G. (2022, March). Efficacy and safety of racemic ketamine and esketamine for depression: A systematic review and meta-analysis. Expert Opinion on Drug Safety. DOI: https://doi.org/10.1080/14740338.2022.2047928
2. Bahji, A., Vazquez, G. H., & Zarate, C. A. (2021). Comparative efficacy of racemic ketamine and esketamine for depression: A systemic review and meta-analysis. Journal of Affective Disorders (278) 542-55. DOI: https://doi.org/10.1016/j.jad.2020.09.071
3. Bennett, R., Yavorsky, C. & Bravo, G. (2022, May 27). Ketamine for Bipolar Depression: Biochemical, Psychotherapeutic, and Psychedelic Approaches. Frontiers in Psychiatry. DOI: https://doi.org/10.3389/fpsyt.2022.867484
4. Bennett, R. (2020, March 20). Recommendations for ketamine clinicians during COVID. KRIYA Institute. https://www.kriyainstitute.com/covid
5. Bennett, R. (2020, December 13). Ethical Guidelines for Ketamine Clinicians. Journal of Psychedelic Psychiatry 2(4), 19-23. https://www.kriyainstitute.com/guidelines
6. Mathai, D. S., Meyer, M. A., Storch, E. A., & Kosten, T. R. (2020, March 1). The relationship between subjective effects induced by a single dose of ketamine and treatment response in patients with major depressive disorder: A systematic review. Journal of Affective Disorders (264) 123-129. DOI: https://doi.org/10.1016/j.jad.2019.12.023
7. Shaw, I. (2022, June 15). Esketamine antidepressant nasal spray rejected by NICE. Pulse Today. https://www.pulsetoday.co.uk/news/clinical-areas/mental-health-and-addiction/esketamine-antidepressant-nasal-spray-rejected-by-nice/